South Korea Hemophilia Market Size, Share, and COVID-19 Impact Analysis, By Type (Hemophilia A and Hemophilia B), By Treatment Type (On-demand and Cure), and South Korea Hemophilia Market Insights, Industry Trend, Forecasts to 2035

South Korea Hemophilia Market Insights Forecasts to 2035

• The South Korea Hemophilia Market Size Was Estimated at USD 155.8 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.57% from 2025 to 2035
• The South Korea Hemophilia Market Size is Expected to Reach USD 347.8 Million by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Hemophilia Market Size is anticipated to reach USD 347.8 Million by 2035, growing at a CAGR of 7.57% from 2025 to 2035. The South Korea hemophilia market is driven by various factors, including growing awareness about disorders, government support, rising prevalence of disease and advancements in treatment.

Market Overview

Haemophilia is a rare genetic bleeding disorder in which blood lacks sufficient clotting factors which leading to prolonged bleeding episodes. It is due to a lack or deficiency of certain clotting proteins, such as Factor VIII or Factor IX, in the blood. The two most common forms are hemophilia A and hemophilia B. Hemophilia shows various symptoms such as frequent nosebleeds, easy bruising, joint pain, and severe bleeding from minor injuries. Hemophilia is managed with a variety of treatments that include replacement therapy, prophylactic therapy, gene therapy, clotting-stimulating drugs, pain management measures, and supportive care. The robust healthcare infrastructure in South Korea, which facilitates the availability of diagnostics and treatment for haemophilia patients, is a primary force behind market expansion. Moreover, the increasing research and development (R&D) activities supported by both private and public investments are giving a boost to the market growth. The growing demand for personalized medicines is a key trend in this market. Additionally, the rise in digital health technology, such as telemedicine and mobile health applications, presents an opportunity for patient engagement and monitoring.  

Report Coverage

This research report categorizes the market for the South Korea hemophilia market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea hemophilia market. Recent market developments and competitive strategies such as expansion, Type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea hemophilia market.

Driving Factors

The increased incidence of hemophilia is a significant driver for this market. Considerable progress has been made in the treatment of hemophilia, e.g., the development of long half-life clotting factors and gene therapies, playing a crucial role in the market growth. Improved care has extended the life expectancy of hemophilia patients. The introduction of several government incentives and grants subsidizing research studies on rare diseases is proving to be a growth driver. Additionally, speedy innovations in telemedicine, which enable patients to consult specialists more easily, particularly those who live in remote areas, further drive the market growth.

Restraining Factors

The rare haemophilic factors require high treatment costs, which limit access to the required therapies. Additionally, there are strict regulations for developing new treatments, which creates complexity and delay in approval, further limiting the market expansion.

Market Segmentation

The South Korea Hemophilia Market share is classified into type and treatment type.

• The hemophilia A segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period.    

The South Korea hemophilia market is segmented by type into hemophilia A and hemophilia B. Among these, the hemophilia A segment held the dominant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the high incidence of hemophilia A in developed regions, as well as ongoing studies on developing preventive treatment. For instance, in August 2025, preventive treatment with Adynovate (rurioctocog alfa pegol) was shown to be effective at preventing bleeding episodes among most children and adults with haemophilia A.

• The on-demand segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.     

The South Korea hemophilia market is segmented by treatment type into on-demand and cure. Among these, the on-demand segment held the largest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to this treatment offers flexibility, addresses bleeding events. Additionally, this further reduces the cost and medication usage. Further, the increasing study on on-demand treatment of bleeding, surgery and/or perioperative coverage, and prophylaxis in paediatric and adult patients with haemophilia B in real-world settings in South Korea.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea hemophilia market, along with a comparative evaluation primarily based on their Type offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes Type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company Limited
• CSL Behring
• Pfizer Inc.
• Novo Nordisk A/S
• Bayer AG
• Roche Holding AG
• Sanofi S.A.
• Octapharma AG  
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea hemophilia market based on the below-mentioned segments:

South Korea Hemophilia Market, By Type

• Hemophilia A
• Hemophilia B

South Korea Hemophilia Market, By Treatment Type

• On-demand
• Cure